Hematologic Oncology | Specialty

Dr. Gisslinger on a Study Comparing Ropeginterferon Alfa-2b to Hydroxyurea in PV

December 6th 2016

Heinz Gisslinger, MD, Medical University of Vienna, discusses the phase III PROUD-PV study, which evaluated ropeginterferon alfa-2b (P1101) for the treatment of polycythemia vera (PV) during the American Society of Hematology (ASH) Annual Meeting.

KTE-C19 Response Rates Spark FDA Submission for Aggressive Lymphomas

December 6th 2016

Treatment with the CD19-directed CAR T-cell therapy KTE-C19 showed a complete remission rate of 73% for patients with aggressive, chemorefractory primary mediastinal B-cell lymphoma and transformed follicular lymphoma.

Dr. Burke on a Study Investigating Obinutuzumab in Large B-Cell Lymphoma

December 5th 2016

John M. Burke, MD, discusses the GOYA study, a phase III study investigating obinutuzumab plus CHOP in patients with previously untreated diffuse large B-cell lymphoma. Burke discussed the study during the American Society of Hematology (ASH) Annual Meeting.

Lirilumab/Azacytidine Combo Safe, Active in AML

December 5th 2016

The combination of the killer-cell immunoglobulin-like receptors inhibitor lirilumab with the hypomethylating agent azacytidine was well tolerated and showed early signals of activity in heavily pretreated patients with acute myeloid leukemia.

Enasidenib Shows Promising Activity for IDH2-Mutant MDS

December 5th 2016

Treatment with enasidenib was active and was well tolerated in pretreated patients with IDH2-mutated myelodysplastic syndrome, including those who failed hypomethylating agents.

Vadastuximab Talirine Yields Rapid and Deep Remissions in Early Study of Patients With AML

December 4th 2016

Researchers are hopeful that the addition of the investigational agent vadastuximab talirine to standard 7+3 induction therapy may improve survival for patients with acute myeloid leukemia.

CTL019 Highly Effective in Global Phase II ALL Study, FDA Submission Anticipated

December 4th 2016

The CAR T-cell therapy CTL019 demonstrated an 82% complete remission (CR) or CR with incomplete blood count recovery rate for pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Dr. Patnaik on a Study Examining SL-401 in Patients With Myeloproliferative Neoplasms

December 4th 2016

Mrinal S. Patnaik, MBBS, hematologist, Mayo Clinic, discusses a study investigating SL-401 in patients with myeloproliferative neoplasms during the American Society of Hematology (ASH) Annual Meeting.

TKI Cessation Strategies Emerging for CML

December 4th 2016

TKIs can safely be stopped or dose-reduced without jeopardizing long-term outcomes for select patients with chronic myeloid leukemia who have obtained a major molecular response.

Impressive Brentuximab Vedotin Data May Change Practice in CTCL

December 4th 2016

Brentuximab vedotin induced responses lasting at least 4 months in 56% of patients with cutaneous T-cell lymphoma versus 13% in patients receiving physician’s choice of standard therapies, according to findings from the phase III ALCANZA trial presented at the 2016 ASH Annual Meeting.

Survival Improves When Older Patients With AML Receive CPX-351 Before Transplant

December 4th 2016

CPX-351 may provide a bridge to successful transplantation for older patients with acute myeloid leukemia with limited treatment options.

Anti-CD22 CAR T-Cell Salvage Therapy Succeeds in Pediatric ALL

December 4th 2016

Anti-CD22 chimeric antigen receptor (CAR) T-cell therapy induced an 80% complete remission rate among children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia, many of whom had prior anti-CD19 CAR T-cell therapy.

Dr. Kantarjian on Future Role of Chemotherapy in Patients With ALL

December 3rd 2016

Hagop M. Kantarjian, MD, professor, department of Leukemia, division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the evolving and future role of chemotherapy in the treatment paradigm of acute lymphoblastic leukemia (ALL).

Future Approaches in Advanced Mastocytosis

December 1st 2016

Clinical Experience with Midostaurin in Advanced SM

December 1st 2016

Phase II Trial of Midostaurin in Advanced SM

December 1st 2016

Rationale for Targeting KIT in Advanced SM

December 1st 2016

Current Treatments for Advanced SM

December 1st 2016

Advanced SM: Diagnosis and Initial Treatment Approach

December 1st 2016

Subtypes and Characteristics of Mastocytosis

December 1st 2016